BioNTech SE (BNTX) ADS
$0.28
(0.25%)
- Add to watchlist
- This stock can be held in a
$0.28
(0.25%)
$0.28
(0.25%)
Share news, reports & tips
-
BioNTech flags weaker 2024 revenues
9 January 2024 13:22
(Sharecast News) - BioNTech forecast 2024 revenues would come in below analyst expectations on Tuesday, as demand for its Covid-19 vaccine continues to wane.
-
BioNTech vaccine revenues to fall sharply as Covid demand wanes
27 March 2023 12:22
(Sharecast News) - BioNTech warned on Monday that revenues would fall sharply this year, as demand for its ground-breaking Covid-19 vaccine wanes.
-
Sales and profits down sharply at BioNTech
7 November 2022 13:21
(Sharecast News) - BioNTech reported a sharp fall in quarterly revenues and profits on Monday, after demand for its Covid-19 vaccine slowed.
-
China approves BioNTech Covid vaccine for use among expatriates
4 November 2022 10:41
(Sharecast News) - China approved BioNTech SE's mRNA Covid-19 vaccine for use among the expatriate population in the People's Republic of China.
-
BioNTech misses Q2 sales forecasts as it prepares possible launch of new Covid vaccines
8 August 2022 15:10
(Sharecast News) - BioNTech reported a larger-than-expected drop in quarterly revenues, even as it progressed on the roll-out of new Covid-19 vaccines and its pipeline of potential cancer treatments.
-
Covid-19 cases surge during latest week due to BA.4 and BA.5 Covid-19 sub-variants
1 July 2022 13:22
(Sharecast News) - The number of new coronavirus cases in Britain jumped again during the preceding week, likely due to the more infectious BA.4 and BA.5 variants of the Omicron variant of Covid-19.
-
BioNTech revenues triple on strong demand for Covid vaccine
9 May 2022 12:44
(Sharecast News) - Quarterly revenues more than tripled at BioNTech, the German biotech said on Monday, following strong demand for its Covid-19 vaccine.
-
Immune system creates neutralising antibodies against Omicron after three exposures
7 February 2022 15:26
(Sharecast News) - German scientists have shown that the human immune system creates an abundant amount of high quality antibodies capable of neutralising Omicron once it has encountered the virus's...
-
Novavax Covid vaccine approved for use in the UK
3 February 2022 14:06
(Sharecast News) - The UK has approved Novavax's Covid-19 vaccine for use in adults, the medicines regulator confirmed on Thursday.
-
Experts debate potential impact of BA.2 'stealth Omicron' subvariant on pandemic
2 February 2022 17:34
(Sharecast News) - Experts continued to debate to what extent so-called 'stealth Omicron', the subvariant of its namesake strain of Covid-19, would lead to another peak in infections.
-
Omicron subvariant is 1.5 times more transmissible than original
31 January 2022 10:58
(Sharecast News) - A new Omicron subvariant known is more transmissible than its forebear which first appeared in South Africa, scientists said at the weekend, although some studies have shown that vaccines...
Company announcements Announcements
No company announcements about BioNTech SE ADS were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.